Supplementary Respiratory Therapy Improves Pulmonary Function in Pediatric Patients with Cerebral Palsy: A Systematic Review and Meta-Analysis.

cerebral palsy pulmonary function quality of life respiratory muscle strength supplementary respiratory therapy

Journal

Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588

Informations de publication

Date de publication:
02 Feb 2024
Historique:
received: 20 12 2023
revised: 24 01 2024
accepted: 29 01 2024
medline: 10 2 2024
pubmed: 10 2 2024
entrez: 10 2 2024
Statut: epublish

Résumé

Despite medical advances, individuals with cerebral palsy (CP) face significant respiratory challenges, leading to heightened hospitalization rates and early mortality among this population. We hypothesize that integrating supplementary respiratory therapy into standard rehabilitation will result in significant improvements in pulmonary function, enhanced respiratory muscle strength, and an overall increase in the quality of life among pediatric patients with CP. A systematic search of literature across five databases was conducted, and random-effects meta-analyses were performed to assess the impact of supplementary respiratory therapy on (a) pulmonary function: forced vital capacity (FVC), forced expiratory volume in 1 s (FEV1), FVC/FEV1 ratio, peak expiratory flow (PEF), and (b) respiratory muscle strength: maximal inspiratory and expiratory pressure (MIP, MEP), and (c) quality of life. Certainty of evidence was determined by the GRADE assessment. Analysis of data from 11 eligible randomized controlled trials revealed clinically meaningful changes in pulmonary function. We found a relevant mean difference (MD) in absolute PEF of 0.50 L/s (95% confidence interval (CI): 0.19; 0.82 This study presents current evidence on the impact of various supplementary respiratory therapies for CP patients classified under gross motor function classification level I-IV, demonstrating clinically meaningful improvements in pulmonary function and respiratory muscle strength. These improvements suggest the potential for an enhanced quality of life. Our findings hold the promise of serving as a foundational reference for potential revisions to conventional rehabilitation care, incorporating supplementary respiratory therapy.

Sections du résumé

BACKGROUND BACKGROUND
Despite medical advances, individuals with cerebral palsy (CP) face significant respiratory challenges, leading to heightened hospitalization rates and early mortality among this population. We hypothesize that integrating supplementary respiratory therapy into standard rehabilitation will result in significant improvements in pulmonary function, enhanced respiratory muscle strength, and an overall increase in the quality of life among pediatric patients with CP.
METHODS METHODS
A systematic search of literature across five databases was conducted, and random-effects meta-analyses were performed to assess the impact of supplementary respiratory therapy on (a) pulmonary function: forced vital capacity (FVC), forced expiratory volume in 1 s (FEV1), FVC/FEV1 ratio, peak expiratory flow (PEF), and (b) respiratory muscle strength: maximal inspiratory and expiratory pressure (MIP, MEP), and (c) quality of life. Certainty of evidence was determined by the GRADE assessment.
RESULTS RESULTS
Analysis of data from 11 eligible randomized controlled trials revealed clinically meaningful changes in pulmonary function. We found a relevant mean difference (MD) in absolute PEF of 0.50 L/s (95% confidence interval (CI): 0.19; 0.82
CONCLUSIONS CONCLUSIONS
This study presents current evidence on the impact of various supplementary respiratory therapies for CP patients classified under gross motor function classification level I-IV, demonstrating clinically meaningful improvements in pulmonary function and respiratory muscle strength. These improvements suggest the potential for an enhanced quality of life. Our findings hold the promise of serving as a foundational reference for potential revisions to conventional rehabilitation care, incorporating supplementary respiratory therapy.

Identifiants

pubmed: 38337582
pii: jcm13030888
doi: 10.3390/jcm13030888
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Auteurs

Erika Kolumbán (E)

Centre for Translational Medicine, Semmelweis University, 1094 Budapest, Hungary.
András Pető Faculty, Semmelweis University, 1125 Budapest, Hungary.

Márton Szabados (M)

Centre for Translational Medicine, Semmelweis University, 1094 Budapest, Hungary.
Pediatric Center, Semmelweis University, 1083 Budapest, Hungary.

Márk Hernádfői (M)

Centre for Translational Medicine, Semmelweis University, 1094 Budapest, Hungary.
Bethesda Children's Hospital, 1146 Budapest, Hungary.

Uyen Nguyen Do To (U)

András Pető Faculty, Semmelweis University, 1125 Budapest, Hungary.

Rita Nagy (R)

Centre for Translational Medicine, Semmelweis University, 1094 Budapest, Hungary.
Heim Pál National Pediatric Institute, 1089 Budapest, Hungary.
Institute for Translational Medicine, Medical School, University of Pécs, 7624 Pécs, Hungary.

Ádám Zolcsák (Á)

Centre for Translational Medicine, Semmelweis University, 1094 Budapest, Hungary.
Department of Biophysics and Radiation Biology, Semmelweis University, 1089 Budapest, Hungary.

Katalin Eszter Müller (KE)

Heim Pál National Pediatric Institute, 1089 Budapest, Hungary.
Institute for Translational Medicine, Medical School, University of Pécs, 7624 Pécs, Hungary.
Department of Family Care Methodology, Faculty of Health Sciences, Semmelweis University, 1088 Budapest, Hungary.

Zoltán Sipos (Z)

Institute for Translational Medicine, Medical School, University of Pécs, 7624 Pécs, Hungary.
Institute of Bioanalysis, Medical School, University of Pécs, 7624 Pécs, Hungary.

Dániel Sándor Veres (DS)

Centre for Translational Medicine, Semmelweis University, 1094 Budapest, Hungary.
Department of Biophysics and Radiation Biology, Semmelweis University, 1089 Budapest, Hungary.

Anett Szőllősi (A)

Bethesda Children's Hospital, 1146 Budapest, Hungary.

Péter Hegyi (P)

Centre for Translational Medicine, Semmelweis University, 1094 Budapest, Hungary.
Institute for Translational Medicine, Medical School, University of Pécs, 7624 Pécs, Hungary.
Institute of Pancreatic Diseases, Semmelweis University, 1085 Budapest, Hungary.

Miklós Garami (M)

Centre for Translational Medicine, Semmelweis University, 1094 Budapest, Hungary.
Pediatric Center, Semmelweis University, 1083 Budapest, Hungary.

Ibolya Túri (I)

Centre for Translational Medicine, Semmelweis University, 1094 Budapest, Hungary.
András Pető Faculty, Semmelweis University, 1125 Budapest, Hungary.

Classifications MeSH